Gary D. Tollefson
#154,167
Most Influential Person Now
Gary D. Tollefson's AcademicInfluence.com Rankings
Download Badge
Psychology Biology
Why Is Gary D. Tollefson Influential?
(Suggest an Edit or Addition)Gary D. Tollefson's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. (1997) (905)
- Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. (2003) (819)
- Antipsychotic drug effects on brain morphology in first-episode psychosis. (2005) (752)
- Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. (1997) (714)
- Olanzapine versus placebo in the treatment of acute mania (1998) (591)
- Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. (2000) (571)
- Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. (2000) (566)
- Olanzapine versus Placebo and Haloperidol (1996) (566)
- Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. (1997) (562)
- A novel augmentation strategy for treating resistant major depression. (2001) (497)
- Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. (2000) (481)
- Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. (2002) (418)
- Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. (1996) (412)
- Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. (2003) (407)
- Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. (2001) (346)
- Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. (1997) (304)
- Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. (2004) (303)
- Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. (1997) (285)
- Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. (2001) (271)
- Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol (1998) (271)
- Rational Design of a Combination Medication for the Treatment of Obesity (2009) (270)
- A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. (1994) (264)
- Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol (1999) (234)
- Synergistic Effects of Olanzapine and Other Antipsychotic Agents in Combination with Fluoxetine on Norepinephrine and Dopamine Release in Rat Prefrontal Cortex (2000) (234)
- Assessing and interpreting treatment effects in longitudinal clinical trials with missing data (2003) (232)
- Safety of olanzapine. (1997) (227)
- Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial (1996) (212)
- Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol (2005) (199)
- The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations (1997) (177)
- Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. (1997) (177)
- Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine (2001) (173)
- A randomized, double‐blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment‐resistant depression (2006) (172)
- Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. (2005) (171)
- Predictors of antipsychotic treatment response in patients with first episode schizophrenia, schizoaffective, and schizophreniform disorders (2003) (169)
- A descriptive analysis of minor depression. (2002) (162)
- Cognitive function in schizophrenic patients. (1996) (161)
- Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. (2009) (158)
- Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression (2000) (144)
- Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses (1998) (141)
- Olanzapine Versus Haloperidol Treatment in First-Episode Psychosis (1999) (141)
- Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study* (2007) (137)
- Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. (1994) (133)
- A Double-Blind, Controlled Comparison of the Novel Antipsychotic Olanzapine versus Haloperidol or Placebo on Anxious and Depressive Symptoms Accompanying Schizophrenia (1998) (125)
- A Double-Blind, Randomized Study of Olanzapine and Olanzapine/Fluoxetine Combination for Major Depression With Psychotic Features (2004) (122)
- Efficacy and Tolerability of an mGlu2/3 Agonist in the Treatment of Generalized Anxiety Disorder (2008) (122)
- Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia (1990) (122)
- A Double-Blind, Placebo-Controlled Clinical Trial of Fluoxetine in Geriatric Patients With Major Depression (1995) (120)
- Long-Term Neurocognitive Effects of Olanzapine or Low-Dose Haloperidol in First-Episode Psychosis (2006) (119)
- Time-lapse mapping of cortical changes in schizophrenia with different treatments. (2009) (117)
- Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. (1998) (110)
- Efficacy of olanzapine: an overview of pivotal clinical trials. (1997) (107)
- Olanzapine versus haloperidol in the treatment of first episode psychosis (1998) (90)
- The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone (1999) (87)
- Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam. (1983) (87)
- Occurrence of myoclonus in patients treated with cyclic antidepressants. (1987) (85)
- A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse (2003) (81)
- Analysis of the Hamilton Depression Rating Scale factors from a double‐blind, placebo‐controlled trial of fluoxetine in geriatric major depression (1993) (77)
- Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder. (2004) (76)
- Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? (1999) (76)
- Ecological Studies of Antidepressant Treatment and Suicidal Risks (2007) (75)
- A Case of Neuroleptic Malignant Syndrome: In Vitro Muscle Comparison with Malignant Hyperthermia (1982) (74)
- Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. (1997) (73)
- Acute Dysphoric Mania: Treatment Response to Olanzapine Versus Placebo (2003) (73)
- A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. (2001) (68)
- The relationship of serum anticholinergic activity to mental status performance in an elderly nursing home population. (1991) (67)
- Olanzapine versus haloperidol in the treatment of schizoaffective disorder (1999) (66)
- Acute Effects of Fluoxetine Versus Placebo on Functional Health and Well-Being in Late-Life Depression (1995) (66)
- The Double-Blind Variable Placebo Lead-in Period: Results From Two Antidepressant Clinical Trials (2001) (65)
- Treatment of Comorbid Deneralized Anxiety in a Recently Detoxified Alcoholic Population with a Selective Serotonergie Drug (Buspirone) (1992) (65)
- Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. (1994) (62)
- Efficacy and safety of long-term fluoxetine treatment of obesity--maximizing success. (1995) (62)
- How long to onset of antidepressant action: a meta‐analysis of patients treated with fluoxetine or placebo (1994) (60)
- Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). (1992) (58)
- Serotonin and alcohol: interrelationships. (1989) (58)
- Comorbid Irritable Bowel Syndrome in Patients with Generalized Anxiety and Major Depression (1991) (58)
- Is Baseline Agitation a Relative Contraindication for a Selective Serotonin Reuptake Inhibitor: A Comparative Trial of Fluoxetine Versus Imipramine (1994) (57)
- Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic (2005) (57)
- Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. (1994) (57)
- Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies. (2005) (52)
- Review of recent clinical studies with olanzapine (1999) (52)
- Anxiety and Alcoholism: A Serotonin Link (1991) (51)
- Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine (1999) (51)
- Controlled, Double-blind Investigation of the Clozapine Discontinuation Symptoms With Conversion to Either Olanzapine or Placebo (1999) (51)
- Comorbid anxious signs and symptoms in major depression: impact on functional work capacity and comparative treatment outcomes (1993) (51)
- The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. (2000) (50)
- The association of buspirone and its metabolite 1-pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency. (1991) (49)
- Anxious–depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy? (1999) (47)
- An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. (2010) (47)
- Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo. (1994) (44)
- Predicting response to fluoxetine in geriatric patients with major depression. (1995) (43)
- Efficacy and Tolerability of an mGlu2/3 Agonist in the Treatment of Generalized Anxiety Disorder (2008) (42)
- No gender differences in placebo responses of patients with major depressive disorder (2001) (42)
- Zonisamide Prevents Olanzapine-Associated Hyperphagia, Weight Gain, and Elevated Blood Glucose in Rats (2008) (42)
- Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms. (2000) (41)
- Olanzapine for Psychotic Conditions in the Elderly (2000) (40)
- A double‐blind trial of fluoxetine, 20 mg, and placebo in out‐patients with DSM‐III-R major depression and melancholia (1993) (39)
- Antidepressant treatment and side effect considerations. (1991) (39)
- Migraine headaches and depression. (1984) (39)
- An open label trial of alprazolam in comorbid irritable bowel syndrome and generalized anxiety disorder. (1991) (39)
- 24 Hour Urinary Dehydroepiandosterone Sulfate in Unipolar Depression Treated with Cognitive and/or Pharmacotherapy (1990) (39)
- Zonisamide-induced mania. (1990) (39)
- Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial. (1999) (38)
- Current issues in the psychopharmacology of schizophrenia (2001) (35)
- A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. The Fluoxetine Collaborative Study Group. (1995) (35)
- Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double‐blind controlled trial (2003) (35)
- Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. (2001) (35)
- Olanzapine vs placebo in the treatment of acute mania (1998) (34)
- Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. (2007) (34)
- Pharmacotherapy of obsessive compulsive disorder‐experience with fluoxetine (1993) (34)
- Latency to rapid eye movement sleep as a predictor of treatment response to fluoxetine and placebo in nonpsychotic depressed outpatients (1994) (33)
- Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders. (1993) (32)
- The Neuroleptic Syndrome and Central Dopamine Metabolites (1984) (32)
- The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease (2001) (31)
- Hypersomnia in major depressive disorders. (1984) (30)
- Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. (2003) (30)
- Prevalence of misuse of prescribed benzodiazepines in patients with primary anxiety disorder or major depression. (1986) (30)
- The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders (2004) (27)
- Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia (2004) (26)
- Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: The absence of an effect related to agitation and suicidal behavior (1997) (25)
- Elevations of urinary MHPG in depressed patients with panic attacks (1987) (25)
- The influence of pharmacotherapy on selfdirected and externally-directed aggression in schizophrenia (1998) (25)
- Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophrenia (2003) (23)
- A comparison of peripheral and central human muscarinic cholinergic receptor affinities for psychotropic drugs. (1982) (22)
- Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group. (1999) (21)
- Clinical and Economic Outcomes of Olanzapine Compared With Haloperidol for Schizophrenia (1999) (21)
- A cholinergic role in the mechanism of lithium in mania. (1983) (21)
- Alprazolam in the treatment of obsessive symptoms. (1985) (20)
- Adverse drug reactions/interactions in maintenance therapy. (1993) (20)
- Skating to where the puck is going to be: a plan for clinical trials and translation research in mood disorders (2002) (20)
- Health economic evaluations of antidepressants: A review (1998) (20)
- Differentiating anxiety and depression. (1990) (19)
- Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: Results from a randomized clinical trial (1998) (19)
- Monoamine oxidase inhibitors: a review. (1983) (17)
- Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol (American Journal of Psychiatry (2003) 160, (1396-1404)) (2009) (16)
- Olanzapine vs. placebo in rapid-cycling bipolar disorder (1998) (16)
- P-13-12 Long-term treatment-emergent dyskinetic symptoms in patients treated with olanzapine and haloperidol (1996) (16)
- Course of psychomotor agitation during pharmacotherapy of depression: Analysis from double‐blind controlled trials with fluoxetine (1996) (16)
- Effect of long-term olanzapine treatment on weight change in schizophrenia (2000) (16)
- Lymphopenia in primary degenerative dementia. (1989) (16)
- Is chronic primary major depression a distinct depression subtype? (1986) (15)
- Inhibitor of antagonist binding to the muscarinic receptor is elevated in Alzheimer's brain (1994) (15)
- The study of olanzapine plus fluoxetine in treatment-resistant major depressive disorder without psychotic features (2000) (14)
- Olanzapine-fluoxetine combination in treatment-resistant depression (2002) (13)
- Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia (2003) (13)
- A comparison of first and second generation antidepressants at the human muscarinic cholinergic receptor. (1983) (12)
- Olanzapine versus haloperidol: Results of the multi-center international trial (1996) (12)
- Hyperadrenergic hypomania consequent to the abrupt cessation of clonidine. (1981) (12)
- Comparison of major depressions with and without panic attacks. (1987) (12)
- 540 Olanzapine versus risperidone in the treatment of psychosis. Preliminary report (1997) (11)
- Does cold winter weather produce depressive symptoms? (1988) (11)
- 539 Treatment failure with clozapine: Can olanzapine be the alternative therapy? (1997) (11)
- Treatment of schizophrenic disorders: Algorithms for acute pharmacotherapy. (1997) (11)
- Olanzapine in the treatment of bipolar depression (2002) (11)
- Thyroxine binding and TSH in recurrent depressive episodes. (1985) (11)
- Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. (1999) (11)
- Comments on Article by Tran and Associates, "Double-Blind Comparison of Olanzapine Versus Risperidone in Treatment of Schizophrenia and Other Psychotic Disorders": Reply (1998) (10)
- Olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders (1998) (10)
- Olanzapine plus fluoxetine: Double-blind and open-label results in treatment-resistant major depressive disorder (1999) (10)
- Olanzapine versus risperidone in the treatment of schizophrenia and related psychotic disorders (1998) (10)
- Is the distinction between situational and nonsituational primary depression valid? (1984) (10)
- A comparison of human muscarinic cholinergic receptor properties subsequent to alcohol abuse and senescence. (1983) (10)
- Depressives syndromes in a primary care setting: evaluation, classification, and outcome. (1983) (10)
- A blinded, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol (1998) (10)
- Indomethacin and prostaglandins: their behavioral relationships in an acute toxic psychosis. (1982) (9)
- Predictors of weight gain during olanzapine treatment (1998) (9)
- Is There a Relationship between Baseline and Treatment-Associated Changes in [3H]-IMI Platelet Binding and Clinical Response in Major Depression? (1996) (9)
- Olanzapine versus risperidone and haloperidol in treatment of schizophrenia (1998) (8)
- SAT-5-5 Olanzapine: An exciting atypical antipsychotic — the clinical experience (1995) (8)
- 541 The course of primary and secondary negative symptoms in a controlled trial with olanzapine (1997) (8)
- Evaluation of depression. (1983) (8)
- A Circulating Lupus‐like Coagulation Inhibitor Induced by Chlorpromazine (1984) (8)
- 544 Olanzapine versus haloperidol in the treatment of first episode psychosis (1997) (8)
- Olanzapine reduces psychosis and behavioral disturbances associated with Alzheimer's disease (1999) (8)
- Delusional hypochondriasis, depression, and amoxapine. (1985) (8)
- The functional-organic dichotomy in new patient evaluations by residents in family practice. (1984) (8)
- P-7-3 Acute and long-term results of the dose ranging double-blind olanzapine trial (1996) (8)
- P-7-5 Olanzapine versus haloperidol: acute results of the multi-center international trial (1996) (7)
- Ionic regulation of antagonist binding to the human muscarinic cholinergic receptor of caudate nucleus. (1982) (7)
- Olanzapine: A novel antipsychotic with a broad spectrum profile (1994) (7)
- A Double-Blind, Placebo-, Bupropion- and Naltrexone-Controlled Study of the Efficacy and Safety of Three Doses of Naltrexone-Bupropion SR Combination Therapy in Obesity: Effects on Total and Visceral Adipose Tissue and CV Risk Markers (2006) (7)
- Olanzapine-fluoxetine combination for psychotic major depression (2002) (7)
- Olanzapine-fluoxetine combination for treatment of psychotic depression (2002) (7)
- Psychiatric implications of anticonvulsant drugs. (1980) (7)
- P.2.015 Olanzapine versus haloperidol: Analysis of schizophrenic patients from the multi-center international trial (1997) (6)
- 363. Olanzapine vs fluphenazine: Treatment of acute schizophrenic symptomatology and anxiety (1998) (6)
- Olanzapine in the treatment of rapid-cycling Bipolar I patients (1999) (6)
- Olanzapine: A promising “atypical” antipsychotic agent (1995) (6)
- Neuropsychiatric sequelae and cephalothin. (1984) (6)
- Olanzapine in the treatment of schizoaffective disorder (1998) (6)
- 543 Olanzapine in the treatment of chizoaffective disorder (1997) (6)
- Olanzapine: Acute and long-term efficacy in bipolar I patients (2000) (6)
- Prediction of postdexamethasone cortisol levels by serum sodium levels in patients with major depression. (1986) (6)
- A blinded trial on the course and relationship of depressive symptoms in schizophrenia (1998) (6)
- Effect of long-term olanzapine treatment on weight change in schizophrenia (2000) (6)
- P.3.058 A comparison of the incidence of long-term treatment-emergent dyskinetic symptoms in patients treated with olanzapine and haloperidol (1996) (6)
- A controlled, double-blind investigation of the clozapine discontinuation syndrome with conversion to either olanzapine or placebo (1998) (5)
- Absence of emergent suicidal ideation during treatment: A comparative, controlled, double‐blind analysis employing several distinct antidepressants (1994) (5)
- P.2.016 The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration (1997) (5)
- Efficacy of olanzapine in the positive and negative symptoms of schizophrenia (1994) (5)
- Olanzapine: Preclinical and Clinical Profiles of a Novel Antipsychotic Agent (2006) (5)
- Metanalysis of olanzapine-fluoxetine use in treatment-resistant depression (2002) (5)
- P.3.016 Olanzapine in the treatment of schizoaffective disorder (1996) (5)
- Costs of olanzapine treatment compared with haloperidol for schizophrenia: Results from a randomized clinical trial (1998) (5)
- 65-86 Olanzapine vs. risperidone in the treatment of psychosis (1997) (5)
- P.3.042 Long-term continuation therapy with the novel antipsychotic olanzapine: A review of the clinical experience (1996) (5)
- The comparative anti-muscarinic-like side effect profiles of olanzapine and risperidone treatment in patients with schizophrenia spectrum psychosis (1999) (5)
- Imipramine metabolism in recurrent depressive episodes. (1985) (5)
- Course and predictors of weight gain in people Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine with first-episode psychosis treated with olanzapine (2005) (5)
- P-7-2 Olanzaplne versus placebo, results of the United-States double-blind olanzapine trial (1996) (4)
- Comments on "Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders" by Tran and Associates: Reply to Kasper and Kufferle (1998) (4)
- P-4-68 Acute and long-term results of the North American double-blind olanzapine trial (1995) (4)
- Association of affective disorder with migraine headaches and neurodermatitis. (1988) (4)
- Antidepressant response in chronic major depression. (1989) (4)
- What is the differential risk of tardive dyskinesia with the novel antipsychotic olanzapine? (1998) (4)
- Distinguishing myasthenia gravis from conversion. (1981) (4)
- Triazolam in the restless legs syndrome. (1985) (4)
- 542 Comorbid mood disturbance in schizophrenia (1997) (4)
- Olanzapine, a new “atypical” antipsychotic (1995) (4)
- S.06.04 The course of primary and secondary negative symptoms in a placebo-and comparator-controlled trial of the typical antipsychotic olanzapine (1996) (4)
- Efficacy of olanzapine, fluoxetine and combination therapy in treatment-resistant major depressive disorder without psychotic features (1998) (4)
- Spermatogenesis during extended lithium treatment. (1989) (3)
- Long-term olanzapine treatment: Efficacy and safety in manic patients with and without psychotic features (1999) (3)
- Delirium induced by the competitive interaction between phenytoin and dipropylacetate. (1981) (3)
- Depression during mania: treatment response to olanzapine or placebo (2000) (3)
- P.1.035 Onset of improvement in emotional and painful physical symptoms of depression with duloxetine treatment (2003) (3)
- OLANZAPINE ON TRIAL. AUTHORS' REPLY (1998) (3)
- OLANZAPINE REDUCES PSYCHOSIS AND BEHAVIORAL SYMPTOMS ASSOCIATED WITH ALZHEIMER's DISEASE (1999) (3)
- 92-1 Treatment consideration for comorbid mood disorders in schizophrenic patients (1997) (3)
- Olanzapine versus haloperidol in schizoaffective disorder, bipolar type: A repeated measures analysis (1999) (3)
- Buspirone: effects on prolactin and growth hormone as a function of drug level in generalized anxiety. (1989) (3)
- A double blind study of olanzapine-fluoxetine combination for treatment of psychotic major depression (2001) (2)
- Additional clinical experience with olanzapine, an “atypical” antipsychotic (1995) (2)
- Use of psychiatric referral by family physicians. (1988) (2)
- Sex and neuroendocrine differences in response to treatment with olanzapine: A preliminary analysis (1998) (2)
- P-7-1 The course of primary and secondary negative symptoms in a controlled trial with olanzaplne (1996) (2)
- combination therapy for the treatment of psychoses. (1997) (2)
- The amobarbital interview in the differential diagnosis of catatonia. (1982) (2)
- S.14.05 Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophrenia (2003) (2)
- Olanzapine reduces psychotic symptoms and behavioral disturbances associated with alzheimer's disease (2000) (2)
- Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with Aizheimer's disease (1999) (2)
- FLUOXETINE AND SUICIDAL IDEATION. REPLY (1990) (2)
- P.3.059 A comparison of extrapyramidal syndromes between olanzapine and placebo in shcizophrenia (1996) (2)
- P.2.062 Olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders (1997) (2)
- The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration (1998) (1)
- P.2.131 Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia (2003) (1)
- P-7-18 Comorbid mood disturbance in schizophrenia (1996) (1)
- Pharmacokinetic properties of maprotiline in geriatric depression. (1989) (1)
- Personality disorders. (1983) (1)
- Erratum: Efficacy of olanzapine in acute bipolar maniana double-blind, placebo-controlled study (Archives of General Psychiatry (2000) 47 (841-849)) (2002) (1)
- Postpartum depression. (1984) (1)
- A retrospective evaluation of plasma trazodone concentrations and clinical response in a primary care clinic. (1988) (1)
- PMH47 WEIGHT GAIN AND IMPROVEMENT IN PSYCHOPATHOLOGY DURING TREATMENT OF SCHIZOPHRENIA WITH ANTIPSYCHOTICS AND WITH PLACEBO (2004) (1)
- The crisis in mental health care: responsibility and accountability. (2002) (1)
- Fluoxetine treatment of panic disorder: A randomized, placebo-controlled, multi-center trial (1998) (1)
- The multi-acting-receptor-targeted-antipsychotic (MARTA) concept of the therapeutic action of olanzapine (2000) (1)
- Drs. Tollefson and Sanger Reply (1998) (1)
- 306. Long-term treatment in panic disorder: Randomization of acute fluoxetine responders to continued treatment with fluoxetine or placebo (1998) (1)
- P.3.017 Extrapyramidal symptoma and tolerability of olanzapine versus haloperidol in acute treatment (1996) (1)
- Olanzapine versus placebo in rapid-cycling bipolar disorder (1998) (1)
- Use of a Long Acting Peripheral Beta Blocker, Nadolol, in Panic Disorder (1984) (1)
- Conversion disorder following termination of pregnancy. (1983) (1)
- Safety metanalysis of olanzapine-fluoxetine combination versus fluoxetine (2002) (1)
- Olanzapine versus haloperidoi treatment in first-episode psychosis (1998) (1)
- FLUOXETINE VS PLACEBO IN MDD: INFLUENCE ON SLEEP LATENCY, PRELIMINARY RESULTS (1992) (0)
- Layered pharmaceutical formulations comprising a rapidly dissolving intermediate layer (2007) (0)
- Use of tomoxetine for the treatment of hyperactivity {t with Aufmerksamkeitsst|rungen (1996) (0)
- Fluoxetine and suicidal ideation. (1990) (0)
- Formulations pharmaceutiques en couches (2007) (0)
- Included Studies (n = 120) (0)
- Recognition and treatment of major depression. (1990) (0)
- Contents, Vol. 22, Supplement 1, 1989 (1989) (0)
- The use of tomoxetine attention deficit hyperactivity disorder (ADHD) Treatment (1997) (0)
- 90-60 Does fluoxetine cause activation, sedation, both, or neither? (1997) (0)
- StandardOlanzapineVersusPlacebo and Ineffective-Dose Olanzapinein the MaintenanceTreatmentof Schizophrenia (1997) (0)
- Dr. Tollefson and Associates Reply (1987) (0)
- 90-61 The course of psychomotor agitation during pharmacotherapy of depression: Analysis from double-blind, controlled trials (1997) (0)
- DOES ANXIETY OR INSOMNIA, AS PART OF MAJOR DEPRESSION, PREDICT A DIFFERENTIAL RESPONSE TO THE TYPE OF ANTIDEPRESSANT PRESCRIBED? (1992) (0)
- Response (1991) (0)
- Safety metanalysis of olanzapine-fluoxetine combination versus placebo (2002) (0)
- Chlorpromazine-Induced Neuroleptic Syndrome (1985) (0)
- OLANZAPINE FOR PRIMARY NEGATIVE SYMPTOMS. AUTHORS' REPLY (1998) (0)
- IS OLANZAPINE A MULTI-ACTING RECEPTOR TARGETED ANTIPSYCHOTIC (MARTA)? (2000) (0)
- Buspirone: effects on prolactin and growth hormone as a function of drug level in generalized anxiety. (1989) (0)
- Dr. Tollefson and Colleagues Reply (1998) (0)
- Health economics of antidepressants: A methodological review (1998) (0)
- Long-term treatment in panic disorder: Randomization of acute fluoxetine responders to continued treatment with fluoxetine or placebo (1998) (0)
- P.3.041 Acute phase efficacy and safety of olanzapine: A review (1996) (0)
- Safety metanalysis of olanzapine-fluoxetine combination versus olanzapine (2002) (0)
- Drug Discovery and Development Methods for Mental Illness (2011) (0)
- Long-term olanzapine-fluoxetine use in major depressive disorder: Interim data (2002) (0)
- Recognition of depressive syndromes, tricyclics, and the second generation antidepressants. (1984) (0)
- P.3.013 Comorbid mood disturbance in schizophrenia (1996) (0)
- Differential actions of the new antipsychotic agents (2000) (0)
- Olanzapine or a pharmaceutically acceptable for the preparation of a medicament for the treatment of autism and mental retardation pharmaceutically acceptable salt. (1996) (0)
- EFFICACY EXPERIENCE WITH OLANZAPINE (1998) (0)
- Using Tomoxet in the treatment of hyperactivity {t with attention disorders. (1996) (0)
- Does pharmacotherapy induce paradoxical worsening in some patients (1993) (0)
- Multilayer pharmaceutical formulations with a rapidly dissolving intermediate layer (2007) (0)
- Alprazolam plus buspirone in treatment of anxiety. (1988) (0)
- Zonisamide Sustained Release Formulation (2006) (0)
- P.1.107 Influence of concomitant medications on fluoxetine in depression clinical trials (1997) (0)
- treatment of inattention and hyperactivity (1997) (0)
- Tomoxetine use for the treatment of induced hyperactivity disorder attention. (1996) (0)
- A Descriptive Analysis of Minor Depression (2005) (0)
- Treatment related suicidality a placebo controlled double blind trial (1991) (0)
- COMBINATION THERAPY FOR TREATMENT OF PSYCHOSES Inventors : (2013) (0)
- SAT-5-7 Biological enrichment in the study of drug: Placebo differences of patients with affective disorders (1995) (0)
- P-7-6 Olanzapine versus haloperidol: Long-term results of the multi-center international trial (1996) (0)
- Depressive episodes following alcohol intoxication. (1982) (0)
- POSTERS (2006) (0)
- Suicidal risk in patients treated with the novel antipsychotic olanzapine (1998) (0)
- Using tomoxetine to treat hyperactivity with attention disorders (1996) (0)
- P-7-4 Acute and long-term results of the North American double-blind olanzapine trial (1996) (0)
- P-15-5 Comparison of extrapyramidal syndromes between olanzapine and placebo in schizophrenia (1996) (0)
- Dr. Garvey and Dr. Tollefson Reply (1987) (0)
- Combination therapy for the treatment of psychosis (1997) (0)
- Evaluation of Suicidalitv During Pharmacolonic Treatmeit of Mgod and NonmoGd Disorders (1993) (0)
- Use of tomoxetine for treating attention-deficit / hyperactivity disorder (1996) (0)
- pharmaceutical formulations comprising a layered intermediate layer rapidly dissolving. (2007) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Gary D. Tollefson?
Gary D. Tollefson is affiliated with the following schools:
